

Index

a

- Acacia willardiana* 160
- N*-acetyl galactosamine (GalNAc) 321, 359
- acid-labile alkyl esters 39
- acid-mediated formation of pGlu 50
- acidolysis 35
- actinomycin D (Dactinomycin®) 259, 260
- acyclic compounds 135, 136
- acyclic triazole peptidomimetics 113–121
- *cis*-amide bond peptidomimetics. 120
 - conditions for 120
 - exchange of dipeptide fragment with 115
 - peptidomimetic inhibitors of HIV-1 protease 114
 - regioselective, sequential Cu-Huisgen synthesis of pseudo-nona-peptidomimetics 118
 - solid-phase Cu-Huisgen backbone and side-chain cycloaddition 114
 - solution-phase synthesis of triazole trimer 116
 - synthesis of
 - 1,4- and 1,5-triazole dipeptide replacements in native protein 119
 - β -turn-inducing 1,4-triazole peptidomimetics 115
- alicyclic β -amino acids
- five-membered alicyclic β -amino acids 175–179
 - amipurimycin 176
 - antifungal activity 177
 - cispentacin 176
 - structure–activity relationship 178
 - synthesis 179
 - *in vitro* activity 180–182
 - medicinal chemistry 175
 - six-membered alicyclic β -amino acids 179–186
 - structure–activity relationship 185
 - synthesis of tilidine 184
 - tachykinin NK1 receptor antagonists 185
- 4-alkylGlu analogs, binding affinities 165
- 4-alkylidene Glu analogs, binding affinities 166, 167
- allophenylnorstatine (Apns) 214
- Alzheimer's disease 220
- Amanita muscaria* 160
- Amanita pantherina* 160
- Amanita strobiliformis* 160
- amastatin 209
- ω -amido group of Asn and Gln 49
- acid-mediated formation of pGlu 50
 - ω -amide protections (selected examples) 50
 - nitrile and aspartimide from unprotected Asn 49
- Z-amino acid azides, from methyl esters 41
- amino acid-based dendrimers
- peptide dendrimers applications
 - as antimicrobial agents 502–504
 - as DNA/RNA delivery vectors 507–512
 - initial efforts on MAPs 502
 - ion sensors and MRI contrast agents 505–507
 - as protein/enzyme mimics 504, 505
 - peptide dendrimer synthesis 491–502
 - glutamic/aspartic acid, proline, and arginine dendrimers 494–497
 - grafted on PAMAM 500–502
 - MAPs synthesis 497–500
 - polylysine dendrimers synthesis 493
- amino acids 135, 247

- side-chain functional groups, entail protection 3
- α -amino acids 151
- bioisosterism 159–162
- AMPA, design and synthesis 160, 161
- thioibotenic acid, design and synthesis 161, 162
- conformational restriction 153–159
- ABHD-V and ABHD-VI 159
- DCAN synthesis 156–158
- LY354740 synthesis 158
- glutamic acid 151–153
- structure–activity studies 162–168
- AMPA analogs 162, 163
- 4-substituted Glu analogs 163–168
- aminoacyl-tRNA synthetases 386
- (2*S*,4*R*)-2-amino-4-(3-(2,2-diphenylethylamine)-3-oxopropyl)pentanedioic acid (DPAG) 168
- 3-amino-2-hydroxydecanoic acid (AHDA) 190, 204, 213
- (*S*)-2-amino-3-(3-hydroxy-7,8-dihydro-6*H*-cyclohepta [*d*]isoxazol-4-yl)propionic acid (4-AHCP) 163
- 3-amino-2-hydroxymethylhexanoic acid (AHMHA) 197, 202, 210
- 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptors 151
- analogs 162, 163
- binding affinities 154, 163
- chemical structures of 163
- design and synthesis 160, 161
- 3-amino-2-hydroxyphenylbutanoic acid (AHPA) 197, 199, 200, 210
- (*S*)-2-amino-3-(3-hydroxy-5-tert-butyl-4-isoxazolyl)propionic acid (ATPA) 163
- functional characterization of 164
- 3-amino-2-oxopropanoate 192
- aminopeptidase P (AP-P) 210
- AP-P inhibitors 210
- aminopeptidases, inhibitors of 207–211
- α -amino protection 2
- non-urethanes 4
- acyl type 4, 5
- alkyl-type groups 11
- benzhydryl groups 12
- diacyl groups 7
- groups cleavable via lactam formation 6
- groups removed by reductive cleavage 8, 9
- monoacyl groups 5
- *N,N*-bis-benzyl protection 12
- phosphine-type groups 10
- phthaloyl (Phth) group 7, 8
- sulfanyl-type groups 13, 14
- sulfonyl-type groups 10, 11
- trifluoroacetyl (*Tfa*) group 5, 6
- triphenylmethyl (Trityl or Trt) group 11, 12
- vinyl groups 12, 13
- urethanes (carbamates/alkyloxycarbonyl groups) 14, 15
- allyloxycarbonyl (Aloc) group 25
- benzyloxycarbonyl (Cbz or Z) group 15–19
- bond, formation of 15
- *tert*-butoxycarbonyl (Boc) group 25–29
- cleaved by β -elimination 19
- cleaved via Michael-type addition 24
- derived from primary alcohols 15
- derived from tertiary alcohols 25
- 9-fluorenylmethoxycarbonyl (Fmoc) group 19–23
- groups derived from secondary alcohols 25
- sulfonylethoxycarbonyl groups 23, 24
- amipurimycin 176
- angiotensin-converting enzyme (ACE) 212
- inhibitors 215
- antibacterial agents 205–207
- antifreeze glycopeptides (AFGPs) 375
- antihyperglycemics
- exendin-4 (*see* Exenatide (Byetta[®]))
- liraglutide 255
- symlin (pramlintide) 254
- antimicrobial peptides 263–267
- daptomycin 266
- gramicidin S 267
- polymyxin 265, 266
- apstatin 209, 210
- arginine dendrimer, structures 497
- aspartyl proteases inhibitors 211, 212
- BACE-1 inhibitors 224–227
- catalytic mechanism 212
- HIV-1 protease inhibitors 216–220
- HTLV-I inhibitors 220, 221
- plasmepsin II inhibitors 222–224
- renin inhibitors 212–216
- asymmetric epoxidation 191
- ($\pm$)-2-azanorbornane-3-*exo*,5-*endo*-dicarboxylic acid (DCAN) 153
- *in silico* studies 154
- synthesis 156–158
- azide–alkyne cycloaddition 372
- α -azido acids, as α -amino acid precursors 33
- azido alanine 108
- aziridine-containing peptides 361
- azlactones 7

b

BACE-1 inhibitors 224–227
 – design and structures 225
Bacillus lentis 368
 benzyl esters 36, 38
 bestatin 205, 207, 208
 – interactions in active site of MAPs 209
 – synthesis 208
 Bestmann–Ohira reagent 107
 bicyclooctane-2-aza-dicarboxylate
 (BOAD) 153
 bioisosterism 159–162
 – case studies
 – AMPA, design and synthesis 160, 161
 – thioibotenic acid, design and
 synthesis 161, 162
 – naturally occurring Glu analogs
 containing 160
 Biopharmaceutics Classification System
 (BCS) 278
N,N-bis-benzyl amino acids 12
 blood coagulation inhibitors
 – bivalirudin 251
 – integrilin (eptifibatide) 251
N-Boc-protected prolinol 120
N-Boc-(2*S*,3*S*)-3-amino-2-hydroxy-5-
 phenylpentanoic acid (AHPPA) 202
 bortezomib (Velcade®) 259
 bovine serum albumin (BSA) 331
 bradykinin 255
 branched peptides
 – as antimicrobials 270
 – solid-phase synthesis of 267
 – as tumor-targeting agents 268–270
N-bromosuccinimide 33
 Brønsted bases 310
 Burgess reagent 5
tert-butyldimethylsilyl (TBS) 346
tert-butyl esters 38, 39

c

calcitonin 256
 calmodulin 459
Campylobacter jejuni 386
 cancer chemotherapy 258
Candida cylindracea lipases (CCL) 192
 carbamate-tethered glycosides 362
 carbocycles, aliphatic and aromatic 136, 137
N-carboxy anhydrides, protection of 31
 ω -carboxy group protection, of asp and glu 55
 – aspartimide formation 55–57
 – ω -esters of asp and glu (selected
 examples) 59
 carboxymethylcyclodextran 232

carboxy protections 3, 28, 34, 35, 39, 40, 55, 57
 – acid-labile esters 39
 – benzyl ester 36
 – *tert*-butyl ester 38, 39
 – cleavage 36
 – substituted benzyl esters 38
 – substituted methyl and ethyl esters 37, 38
 – α -carboxy protectors as precursors to 41
 – methyl and ethyl esters 35, 36
 – selected carboxy protections 40
 – substituted methyl and ethyl esters 36
 – temporary α -carboxy protection 39, 41
 cell-based receptor activation assays 284
 central nervous system (CNS) 151
 cerium ammonium nitrate (CAN) 346
 chiral acylchloride strategy 306
m-chloroperbenzoic acid (mCPBA) 11
 chymotrypsin 214
 circular dichroism (CD) 114
 cispentacin
 – antifungal activity 175, 177
 – structure 176
 – structure–activity relationship 176
 – *in vitro* activity 180–183
 cleavage
 – of APP by BACE 224
 – conditions for (see carboxy protections;
 ω -amide protections)
 – by different peptidases 269
 – of ester linker 430
 – of Fmoc group 83
 – groups removed by reductive 8
 – Leu–Pro cleavage site 220
 – mechanism of Na-Bsmoc cleavage 24
 – N^{α} -Dim group, by bromination 13
 – N^{α} -Nps group 14
 – N^{α} -Phth group 8
 – N^{α} protection via lactam formation 6
 – of peptide resins 423
 – of peptides from solid support 400
 – by proteases 409
 – selective, phenacyl ester in presence of 85
 – of *t*Bu-ester 326
 – with TFA 343
 – thiolytic cleavage of N^{α} -Dts protection 9
 – for urethane protections 16
 – cleaved by β -elimination 19
 coagulation disorders 251
 CODES™ technology 287
 colistin 265
 combinatorial chemistry 395
 computational design, of proteins 473
 confocal microscopy 414
 conformational restriction 153–155

- case studies
 - synthesis of ABHD-V and ABHD-VI 159
 - synthesis of DCAN 156–158
 - synthesis of LY354740 158
 - conformationally restricted Glu analogs 155
 - mechanism of iGluR activation 156
 - coumarin derivatives 233
 - cross-metathesis 378
 - protein modification by transition metals 379
 - sulfur-assisted 380
 - synthesis of neoglycosides via 380
 - CuAAC. *see* Cu(I)-catalyzed azide-alkyne click cycloaddition (CuAAC)
 - Cu-Huisgen cycloaddition reaction 103
 - applications 103
 - mechanism for 104
 - mechanistic consideration for 103–106
 - pseudo-nona-peptidomimetics, regioselective, sequential synthesis 118
 - Cu(I)-catalyzed azide-alkyne click cycloaddition (CuAAC) 372
 - applications 373
 - Danishefsky's glycosyl amino acid syntheses 382
 - pentavalent vaccine construct 383
 - synthetic vaccine against small-cell lung cancer 384
 - vaccine constructs synthesis 381
 - azide-alkyne cycloaddition 372
 - 1,4-disubstituted triazoles as peptide isosteres 373
 - and neoglycoproteins 376–378
 - neoglycoside and neoglycopeptide synthesis via 373–376
 - Curtius rearrangement 176
 - cyclic triazole peptidomimetics 109–113
 - cyclization by Cu-Huisgen cycloaddition, lactamization fail to 113
 - monocyclization vs. cyclodimerization 109
 - self-assembling backbone modified peptidomimetics 112
 - substitution of trans-amide bond in 112
 - VEGFR1 antagonists, synthesis by Cu-Huisgen on-resin cycloaddition 111
 - cyclodimerization 109–111
 - cyclohexylnorstatine 203, 204, 214
 - cyclonorstatine 214
 - cyclooctadiene (COD) ligand 105
 - cyclosporine 22, 24, 257
 - cysteine side-chain modifications 366
 - alkylation 367
- d**
- dehydroalanine (Dha) 361, 368
 - dendrimers. *see* peptide dendrimers
 - 6-deoxy-6-aminohexoses 385
 - deprotection reactions 81
 - cleavage of
 - Boc group with TMS/phenol 84
 - *tert*-butyl ester using $\text{BF}_3 \cdot \text{Et}_2\text{O}$ 84, 85
 - Fmoc group 83
 - phenacyl ester in presence of N^x -nosyl group 85
 - conversion of DCHA salt of N^x -protected amino acids into 85, 86
 - deprotection of Pbf group from Z-Arg(Pbf)-OH 85
 - removal of
 - Boc group with TFA 84
 - Nps group 81, 82
 - phenoc group through photolysis 85
 - phth group by hydrazinolysis 81
 - Trt group 85
 - Z group 82, 83
 - selective methyl ester hydrolysis 84
 - transprotection of N^x -protecting groups: Fmoc-Met-OH to Boc-Met-OH 84
 - designing modular proteins 474
 - desmopressin 251
 - diaminopropionic acid (Dap) 504
 - 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 112
 - diazacyclohexanones 139
 - dichloromethane (DCM) 5, 104
 - dicyclohexylamine (DCHA) salt 201
 - dicyclohexylcarbodiimide (DCC) 197, 406
 - 2',3'-dideoxykanamycin A 207
 - Diels–Alder reaction 370
 - diethylenetriaminepentaacetic acid (DTPA) 506
 - Digena simplex* 152
 - N,N'*-diisopropylcarbodiimide (DIC) 399
 - diisopropylethylamine (DIPEA) 9, 104, 343
 - 4,5-dimethoxy-2-nitrobenzyloxycarbonyl (Nvoc) 57
 - 2-(3,5-dimethoxyphenyl)prop-2-yloxycarbonyl (Ddz) 57
 - N,N*-dimethylformamide (DMF) 8, 104
 - 3,5-dimethylpyrazole 197
 - dimethyl (methylthio)sulfonium triflate (DMTST) 340
 - dimethylsulfoxide (DMSO) 104
 - dipeptide
 - formation 30
 - impurities 29
 - synthesis 3

diphenylmethanimine 5
 disubstituted Fc-peptide dendrimers,
 structures 496
 DNA polymerase 455
 docetaxel 228
 drug discovery 101
Dysidea herbacea 153

e

edeines 205, 206
 electroporation 455
 enfuvirtide. *see* fuzeon
 erythropoietin (EPO) 346
Escherichia coli 210, 376
 estrogen receptor β (ER- β) 341
 – synthesis 341
 1-ethyl-3-(3-dimethylaminopropyl)
 carbodiimide hydrochloride (EDC) 370
 ethyl esters 35, 36
 Evans-Sjögren ketenes 305, 308, 309
 excitatory amino acid transporters
 (EAATs) 152
 exenatide (Byetta®) 254, 255
 experimental procedures
 – monitoring and characterizing
 triazoles 121, 122
 – for 1,4-triazoles synthesis using Cu-Huisgen
 cycloaddition 122, 123
 – for 1,4-triazoles synthesis using Ru-Huisgen
 cycloaddition 123

f

factor IXa 184
 factor Xa inhibitors 183
 9-fluorenylmethylpentafluorophenylcarboante
 (Fmoc-OPfp) 33
 Fmoc donors 30
 Fmoc-2-mercaptobenzothiazole (MBT) 30
 formulation technologies
 – absorption enhancers 284, 285
 – coadministration with protease
 inhibitors 285
 – formulation vehicles 285, 286
 – site-specific delivery 286, 287
 fucosyl-peptide dendrimers 503
 furin 465
 fuzeon 257

g

gadomer structure and computer generated
 model 507
 gene/dendrimer cargo, internalization
 pathway 509
 Gibbs free energy equation 153

β -glucosidase 459
 glutamatergic neurotransmitter system
 – malfunctioning 152
 – receptor and transporter subtypes in 152
 glutamic acid 151–153
 – dendrimers synthesis 494, 495
 – low-energy conformations 155
 glutathione disulfide 345
 glycoconjugation 364
 glycopeptide 360. *see also* N-glycopeptides; O-
 glycopeptides
 – strategies for synthesis 361
 N-glycopeptides synthesis 342–353
 – erythropoietin N-glycopeptide fragment
 1–28
 – biantennary dodecasaccharide
 synthesis 346–348
 – reagents and conditions 347, 348
 – HIV GP120 V3 domain N-glycopeptide,
 chemoenzymatic synthesis
 – Fmoc-GlcNAc-Asn amino acid building
 block synthesis 351
 – oxazoline tetrasaccharide donor
 synthesis 350, 351
 – V3 cyclic GlcNAc peptide and endo A
 coupling with 352, 353
 – N-glycopeptide fragment 1–28 348, 350
 – reagents and conditions 349
 – RNase C glycoprotein synthesis 343–345
 O-glycopeptides synthesis 324–341
 – estrogen receptor peptides synthesis,
 conformational analysis 340, 341
 – Fmoc-GlcNAc-Ser/Thr amino acids
 synthesis 340
 – mucin-type glycopeptides synthesis
 – glycopeptide recognition domain, synthesis
 of 331–339
 – glycopeptide vaccines, synthesis 325–331
 – tumor-associated glycopeptides,
 synthesis 325–331
 glycoproteins 359
 – enzymatic glycoprotein synthesis 385
 – generation
 O-glycosidic bond 359
 glycosylated cyclic arginine–glycine–aspartate
 (RGD) derivatives 375
 glycosylation 359
 – using Diels–Alder chemistry 370
 – via disulfide formation 367
 gonadotropin-releasing hormone agonists and
 antagonists 251–253
 – cetorelix 253
 – degarelix 253
 – gonadorelin 251, 252

- lupron(leuprolide) 252
- G-proteins 463
- Grignard reagents 309
- Grob fragmentation 32
- guanidino group of Arg, protection of 43
 - Arg precursors 45
 - Arg protections (selected examples) 46
 - nitration 44, 45
 - protection through protonation 43
- h**
- hemolytic index (HI) 502, 503
- hetero-bifunctional linkers 371
- hetero Diels–Alder reaction 156
- hexyl-insulin monoconjugate 2 (HIM2) 283
- high-performance liquid chromatography (HPLC) 64, 85, 110, 314, 330, 331, 333
- high-throughput synthesis, of peptides 396.
 - see also* parallel peptide synthesis
 - directed sorting 400–402
 - parallel peptide synthesis 396–400
 - synthesis of peptide arrays 402–405
 - Fodor's technology 402, 403
 - MAS technology instrument 403
 - synthesizers 405
 - technological developments 404
- histo-aspartyl protease (HAP) 222
- HIV GP 120 V3 domain *N*-glycopeptide,
 - chemoenzymatic synthesis 352
- HIV-1 protease 216
 - inhibitors 133, 139
 - design and structure 217
 - potent peptidomimetic inhibitors 114
 - synthesis of 114
 - prodrugs of inhibitors 219
- HIV reverse transcriptase 459
- homophenylalanine 202
- homoserine 108
- Hoveyda–Grubbs catalyst 379, 380, 382
- HTLV-I protease inhibitors
 - as anti-AIDS drugs 221
 - design and structures 221
- Huisgen cycloaddition
 - acyclic triazole peptidomimetics 113–121
 - Cu-Huisgen cycloaddition reaction 103–106
 - applications of 103
 - mechanistic consideration for 103–106
 - cyclic triazole peptidomimetics 109–113
 - [2+3] cycloaddition between azides and acetylenes 102, 103
 - in peptidomimetic chemistry 101
 - Ru-Huisgen cycloadditions, mechanistic consideration for 103–106
 - thermal cycloaddition 102
 - triazole-modified peptidomimetics
 - synthesis, building blocks for 106–109
- human HeLa cells 512
- hydrogen bonding, schematic representation 136, 142
- α -hydroxy- β -amino acids 189
 - occurrence of 189
 - structure of 190
 - from marine organisms 190
 - naturally occurring 190
 - synthesis of 191
 - 3-amino-2-hydroxydecanoic acid and its analogs 204
 - isoserine 191–193
 - isothreonine 193–196
 - norstatines 197–204
 - phenylisoserine 197
 - synthetic demands 205
- p*-hydroxybestatin 208
- hydroxy group of Ser, Thr, protection of 54
 - protectors of 54
- hydroxylysine 359
- N*-hydroxysuccinimide (NHS) ester 370
- hypothalamic neurosecretory neurons 250
- i**
- ibotenic acid (IBO) 160
- icatibant (Firazyr®) 255, 256
- iGluR activation, mechanism 156
- imidazole group of His, protection of 45–48
 - His protections 48
 - *N*²-Bom-substituted His, preparation of 47
 - unprotected His
 - electrophilic substitution of indole ring of 47
 - racemization of 47
- imine
 - from chiral aldehydes 298
 - *E/Z* isomerization 297
- indole group of Trp, protection 48, 49
 - side-reactions of unprotected Trp 48
- α -integrin receptor 233
- intestinal drug permeability
 - mechanisms 279
- N*-iodoacetyl glycosylamines 384
- isocyanates 363
- isocyanato peptides, synthesis of 6
- isoserine 191
- isothreonine 193–196
- k**
- kanamycin 207
- keyhole limpet hemocyanin (KLH) 381

Kinugasa reaction 314, 315
 – catalysts for 315
 – with Cu (II) catalyst 316
 Kochetkov anomeric amination 348
 Kochetkov method 343
 Koenigs–Knorr reaction 364

I

β -lactamase 459
 β -lactams, asymmetric synthesis
 – arenechromium imines 302
 – by azaferrocene catalyst 314
 – bis-aldimines 308
 – *N*-bis(trimethylsilyl)methyl imines 306
 – *N*-Boc- α -aminoimines 300
 – catalysts influence on stereoselectivity 309–317
 – – β -lactams 106 with proton sponge 312
 – – Kinugasa reaction with Cu (II) catalyst 316
 – – tandem nucleophile/Lewis acid-promoted synthesis 312–314
 – – trans- β -lactams 113, catalytic asymmetric synthesis of 314–316
 – with chiral catalysts 312
 – chiral imines 302
 – chiral substituents influence on stereoselectivity 298
 – double asymmetric cycloinduction 308, 309
 – Evans-Sjögren ketenes 309
 – imine 301, 303, 304
 – – component, asymmetric induction 298–305
 – – geometry influence on stereoselectivity 294, 295
 – – isomerization influence, nucleophilic attack onto ketene stereoselectivity 296, 297
 – ketene 301, 303, 304
 – – component, asymmetric induction 305–308
 – Lewis acid/nucleophile synthesis 313
 – order of addition influence of reactants 297, 298
 – solvent polarity influence on stereoselectivity 296
 – symmetrical/unsymmetrical ketimines 307
 – unsubstituted imines 307
 – via Staudinger reaction (*see* Staudinger reaction)
 Lansbury method, for glycopeptides 342
 β -letosulfide 201
 leucine aminopeptidase 208
 ligand-binding domain (LBD) 155

lipid dendrimer 508, 510
 lysine side-chains modifications 368–370

m

macrocyclic human renin inhibitors 215
 macrocyclic peptidomimetics 133–135
 macro-lactonization strategy 113
 magnetic resonance imaging (MRI) 505, 506, 513
 matrix-assisted laser desorption ionization (MALDI)-MS 413
 membrane-bound glycoprotein mucin 1 (MUC1) 325
 4-mercaptophenylacetic acid 378
O-mesitylenesulfonylhydroxylamine (MSH) 368
 metalloaminopeptidases (MAPs) 208
 metallopeptidases 208
 metalloproteases 465
 methanethiosulfonate (MTS) 367
p-methoxy benzyl (PMB) 346
 4-methoxyphenacyloxy-carboxyl (Phenoc) 57
N-methyl- α -amino acids (NMAs) 7, 22
 4-methylbenzhydrylamine (MBHA) resin 110
p-methylbestatin 208
 methyl (*S*)-Boc- δ -azido-norvalinate synthesis 109
N-methyl-D-aspartic acid (NMDA) receptors 151
 methyl esters 35, 36
 – group, structure–activity relationship 185
N-methylmorpholine (NMM) 31, 203, 233, 363
 4-methylpiperidine 399
 methylsulfonyl triflate (MeSOTf) 326
 7-methyl-,5,7-triaza-bicyclo[4.4.0]dec-5-ene (MTBD) 34
 Michael acceptor 368
 Michael addition–cyclization process 304, 305
 Michaelis–Menten kinetics 504
 microsclerodermin A 190
 Mitsunobu reaction 108
 monocyclization 110
 mucin-type glycopeptides synthesis
 – glycopeptide vaccines synthesis 325–331
 – – MUC1–OVA glycopeptide vaccines 330
 – – reagents and conditions 326–329
 – P-selectin glycoprotein ligand-1 synthesis, glycopeptide recognition domain 331–339
 – – PSGL-1 glycopeptides 337–339
 – – reagents and conditions 334, 335

- sialyl-T antigen-BSA conjugate 332, 333
- T antigen-BSA conjugate 332, 333
- structure 322, 323
- tumor-associated glycopeptides 325–331
- reagents and conditions 326–329
- mucosal cell permeability 278
- MUC1–OVA glycopeptide vaccines, synthesis 330
- multicomponent reactions (MCRs) 5
- multidrug-resistant (MDR) gram-negative pathogens 266
- multiple antigenic peptides (MAPs) synthesis 497–500
- designs 500
- initial efforts on 502
- ligating unprotected peptides, chemoselective methods for 499
- schematic diagram for 498
- multivalency effect, thermodynamic model 499

n

- N^{α} -Dts-protected amino acids 9
- N^{α} -Dts protection, thiolytic cleavage of 9
- N^{α} , N^{ϵ} -bis-protected amino acids 32
- N^{α} -Nps-protected amino acids 13
- N^{α} -Phth-amino acids 7
- N^{α} -protected peptide acid 3
- N^{α} -protecting groups 32
- in synthesis of NMAs 33, 34
- N^{α} protection. *see* α -amino protection
- N^{α} -sub-amino acids 12
- native chemical ligation (NCL) 343
- N^{α} -Trt-protected amino acids 12
- natural peptides, degradation 248
- natural proteins 473
- N^{α} -urethane protections, interconversion of 31
- neoglycopeptide 360, 361
- application, as synthetic vaccines 380–384
- C-glycosides 365
- C=N linkage 365, 366
- N-glycosides 362–364
- O-glycosides 364
- S-glycosides 361, 362
- via CuAAC 373–376
- neoglycoproteins 361
- CuAAC and 376–378
- nesiritide (Natreacor®) 249
- neurotensin
- structure 270
- tetra-branched forms 269
- p*-nitrobestatin 208
- p*-nitrophenyl anthranilate (PNPA) 371
- nonsymmetric dendrimers 507
- nuclear magnetic resonance (NMR) spectroscopy 116, 120, 133

o

- Octreoscan™ 262, 263
- octreotide 260, 261
- Ojima–Holton β -lactam coupling method 197
- oligopeptides 1, 2
- as antibacterial agents 205
- binds to $\alpha_v\beta_3$ integrins 506
- formation, during introduction of N^{α} -urethane protections 30
- reaction mechanism for formation of 30
- transporter (PEPT1) 281
- one-pot N^{α} protection 33
- oxazolidinone 34
- oxytocin 249, 250
- ozonolysis 364

p

- paclitaxel
- analogs, clinical trials 231
- and derivatives 228
- DAB 228
- docetaxel 228
- plasmin-sensitive prodrug 233
- prodrugs in advanced, clinical trials 232
- structure of 228
- synthesis
- of IDN 5109 and SB-T-1214 229
- of isotaxel and release mechanism of paclitaxel 231
- of 3'-*N*-acyl-paclitaxel analogs 230
- and release mechanism of paclitaxel plasmin-sensitive prodrug 233
- route for paclitaxel analogs 229, 231
- parallel peptide synthesis 396
- diketopiperazine linker release 398
- Frank's synthesis on paper circles 396
- Geysen's pin synthesis 397
- use of lanterns 397
- Houghten's technique of tea-bag synthesis 397
- new instruments 398–400
- centrifugal DNA and peptide synthesizer 399
- Tetras™ 398
- peptide cleavage from solid support 397, 398
- parathyroid hormone 256, 257

- peptide dendrimers. *see also* amino acid-based dendrimers
 - applications
 - as antimicrobial agents 502–504
 - as DNA/RNA delivery vectors 507–512
 - initial efforts on MAPs 502
 - ion sensors and MRi contrast agents 505–507
 - as protein/enzyme mimics 504, 505
 - catalysis of ester hydrolysis 504
 - synthesis 491–502
 - of cyclic peptide dendrimers 500
 - glutamic/aspartic acid, proline, and arginine dendrimers 494–497
 - grafted on PAMAM 500–502
 - MAPs synthesis 497–500
 - polylysine dendrimers synthesis 493
- peptide drugs
 - antimicrobial peptides 263–267
 - Daptomycin 266
 - Gramicidin S 267
 - Polymyxin 265, 266
 - availability in market 249–258
 - antihyperglycemics 254, 255
 - blood coagulation inhibitors 251
 - calcitonin 256
 - cyclosporine 257
 - desmopressin 251
 - fuzeon 257, 258
 - gonadotropin-releasing hormone agonists and antagonists 251–253
 - icatibant 255, 256
 - natriuretic peptide (Nesiritide) 249
 - oxytocin 249, 250
 - parathyroid hormone 256, 257
 - sermorelin 256
 - vasopressin 250
 - intestinal absorption, fundamental considerations 277–279
 - oncology, approved peptides in 258–263
 - actinomycin D 259, 260
 - bortezomib 259
 - narimastat 260
 - Octreoscan™ 262, 263
 - octreotide 260, 261
 - vapreotide 261, 262
 - oral bioavailability 277
 - formulation technologies 284–287
 - improvement strategies 280–287
 - limiting barriers 279–280
 - perspectives 267–270
 - branched peptides as antimicrobials 270
 - branched peptides as tumor-targeting agents 268–270
- peptide libraries
 - future of 421
 - omission libraries 408
 - orthogonal libraries 408, 409
 - peptide mixtures, synthesis of 406–409
 - positional scanning libraries 406
 - solution-based screening, of OBOC libraries 418–421
 - synthesis of peptides, on mixture of particles 409–416
 - automated bead picking system 414
 - bead sorting instrument for OBOC 413
 - determination of structure of peptide on 416–418
 - hit isolation through magnetic bead sorting 412
 - one-bead–one-compound (OBOC) technology 409, 410, 415
 - one-bead–two-compounds assay 411
 - synthesis of hexapeptide library 416
 - validation 413
 - synthetic protocols 421
 - dual-layer beads, preparation of 425, 426
 - library of libraries, preparation of 426
 - OBOC libraries for testing in solution, preparation of 426–431
 - pin synthesis 421, 422
 - split-and-mix synthesis of OBOC noncleavable libraries 424, 425
 - SPOT synthesis 422
 - synthesis in tea-bags 422, 423
 - synthesis on cotton 423, 424
- peptides 1, 11, 20, 29, 35, 38
 - antimicrobial 263, 264, 270, 502, 503
 - biostability of 249
 - cationic 265, 270
 - combinatorial 458, 459, 461, 465
 - containing difficult sequences as useful tool for 220
 - crude 423
 - dendrimeric 502
 - as drugs 249
 - library (*see* peptide libraries)
 - natural 248
 - oligo-branched 268
 - synthesis using cystine as self-protected Cys 51–53
 - tetra-branched neurotensin 270
 - therapeutic 264
 - Z group-protected 82
- peptidomimetic drugs

- intestinal absorption, fundamental considerations 277–279
 - oral bioavailability 277
 - limiting barriers 279, 280
 - Perlman's catalyst 306
 - Peyer's patches 286
 - phage vectors 452
 - combinatorial peptide libraries, generation of 455–458
 - Kunkel mutagenesis approach 457
 - modified protocol 456, 457
 - M13 bacteriophage 452, 453
 - phage-displayed combinatorial peptide libraries
 - advantages 452
 - alanine scanning for 460
 - disadvantages 452
 - identifying peptide ligands
 - binding to cell surfaces 463, 464
 - to surfaces of inert materials 465
 - mapping protease specificity 464, 465
 - mapping protein–protein interactions 461–463
 - phage ELISA 461
 - screening, for peptide ligands to target proteins 458–460
 - phage-display particles, types of 453
 - type 3 or 8 displaying, combinatorial peptides 453, 454
 - phebestin 210, 211
 - phenolic group of Tyr, protection 54
 - protectors of 55
 - phenylisoserine 197
 - phenylnorstatine 197
 - phenylthiosulfonate (PTS) 367
 - phosphoadenosyl phosphosulfate (PAPS) 336
 - photocleavable carboxy protectors 57
 - photocleavable protections 57
 - advantages of 57
 - phthaloylating reagents 8
 - plasmepsin II inhibitors 222–224
 - Plasmodium falciparum* 222
 - poly(amido amine) (PAMAM)
 - dendrimers 491, 500, 501
 - synthesis 501
 - polylysine dendrimers synthesis 493
 - Polymyxins 265, 266
 - polypeptides 1
 - linear 513
 - N^{α} -deprotection 14
 - polypropylene imine (PPI) 491
 - post-translational modifications 1
 - probestin 211
 - prodrug approach, for oral bioavailability of
 - peptide-based drugs 280, 281
 - prostate-specific antigen 465
 - protease inhibitors 285
 - protease–ligand complexes 132
 - proteases 462, 464
 - protection reactions 2, 59
 - general procedure, for preparation of 59
 - amino acid benzyl ester *p*-toluenesulfonate salts 70, 71
 - amino acid ethyl esters 69, 70
 - amino acid methyl ester hydrochloride salts 68, 69
 - amino acids using pentafluorophenyl carbonate 80, 81
 - *tert*-butyl esters of N^{α} -unprotected amino acids 71–80
 - N^{α} -Aloc-amino acids 65
 - N^{α} -Boc-amino acids 65–67
 - N^{α} -Bpoc-amino acids 67, 68
 - N^{α} -Bsmoc-amino acids 64, 65
 - N^{α} -Fmoc-amino acids 62–64
 - N^{α} -Ns-amino acids 60
 - N^{α} -Nsc-amino acids 64
 - N^{α} -phthaloyl amino acids using *N*-(ethoxycarbonyl)phthalimide 59
 - N^{α} -Trt-amino acids 59, 60
 - N^{α} -Z-amino acids 61
 - Tfa-Arg-OH 59
- protectors
- of hydroxy group of Ser/Thr 54
 - of phenolic function of Tyr 55
- protein design methods 475, 476
- computational design 476, 477
 - computational enzyme design 477, 478
 - results of computational design experiments 478–480
 - β -barrel 478, 479
 - β -sheets 478, 479
 - TIM-barrel 478, 479
 - top7 479
 - directed evolution methods 480
 - expression systems and assays 481, 482
 - randomization strategies 480, 481
- protein design, protocol for 484–486
- RosettaDesign 485, 486
 - RosettaHoles method 486
- protein interfaces, design of 482–484
- proteinogenic amino acid 2
- protein–protein interactions 461, 463
- protein side-chain modifications 366
- modifications of
 - cysteine side-chains 366–368

- fluorescent anthranilamide-linked glycoconjugate 371
- hetero-bifunctional linkers 371
- lysine side-chains 368–370
- protein structure databases 474
- P-selectin glycoprotein ligand-1 (PSGL-1) 331
- chemoenzymatic synthesis 338, 339
- synthesis 337
- Pseudomonas aeruginosa* 503
- pyridinium chlorochromate (PCC) 201
- q**
- (S)-quisqualic acid (QUIS) 160
- Quisqualis indica* 160
- r**
- racemization 6, 7
- and β -elimination in S-protected Cys residues 53
- of N^α -acyl- α -amino acid derivatives 7
- recombinant DNA technology 248
- reductive amination 364
- regioselectively addressable functionalized templates (RAFTs) 365
- renin–angiotensin system (RAS) 212
- restriction process 153
- retro-synthetic analysis 155
- ribosomes 1, 205
- RNase C enzyme 345
- RNase C glycoprotein
- synthesis 344, 345
- fragments 344
- through NCL 345
- RNase fragment 344
- rotating-frame Overhauser spectroscopy (ROESY) 137
- ruthenium-catalyzed Huisgen cycloaddition 103
- mechanistic consideration for 103–106
- Ru-catalysts, synthesis of 105
- s**
- Sclerochiton ilicifolius* 153
- scytanemin A 190, 191
- secondary amide bond 1
- self-assembling backbone modified peptidomimetics 112
- serine 108, 321, 326, 340, 359, 381, 407, 421
- serine proteases 465
- sermorelin 256
- severe combined immunodeficiency (SCID) 186
- sialic acid 321
- sialyl-T antigen–BSA conjugate
- synthesis 332, 333
- side-chain protection
- ω -amido group of Asn and Gln 49, 50
- ω -amino group of diamino acids 41–44
- guanidino group of Arg 43
- Arg precursors 45
- nitration 44, 45
- protection through protonation 43
- imidazole group of His 45–48
- indole group of Trp 48, 49
- β -thiol group of Cys 50, 51
- silyl ester protection 41
- solid-phase chemistry 395
- solid-phase peptide synthesis (SPPS) 4, 360, 395
- solid-phase synthesis 104, 116
- split-and-mix combinatorial peptide dendrimer library 505
- S-protected cys derivatives, common
- side-reactions with 51
- ω -carboxy group of Asp and Glu 55
- aspartimide formation 55–57
- β -elimination 51
- hydroxy group of Ser, Thr, and phenolic group of Tyr 54
- protectors of the hydroxy group of Ser/Thr 54
- protectors of the phenolic function of Tyr 55
- oxidation 51
- racemization 51
- synthesis of peptides using cystine as self-protected Cys 51–53
- thioether group of Met 53, 54
- standard Kaiser test 122
- Staudinger reaction 293, 294. *see also*
- β -lactams, asymmetric synthesis
- asymmetric induction
- from imine component 298–305
- from ketene component 305–308
- chiral catalysts for 311
- diastereoisomeric excess 296
- double asymmetric cycloinduction 308, 309
- influence of
- catalysts on stereoselectivity 309–312
- chiral substituents on 298
- geometry of imine on stereoselectivity in 294, 295
- isomerization of imine 296, 297
- polarity of solvent on 296

- mechanism 294, 311
 - reduction approach 122
 - stereochemistry of 295
 - β -strand mimetics
 - acyclic compounds 135, 136
 - aliphatic and aromatic carbocycles 136, 137
 - ligands containing
 - one/multiple rings with one heteroatom 138, 139
 - one ring with one heteroatom 137, 138
 - one ring with two heteroatoms 139
 - one ring with two/three heteroatoms 140
 - two rings with one heteroatom 140, 141
 - two rings with two/three heteroatoms 141, 142
 - macrocyclic peptidomimetics 133–135
 - recent advances in 129
 - β -sheets 130
 - β -strands 129
 - composed of Ala residues 130
 - strand/sheet/turn/helix recognition, differences in 130, 131
 - towards β -strand mimetics 131–133
 - Streptomyces olivoreticuli* 207
 - structure–activity studies 162–168, 178
 - case studies
 - AMPA analogs 162, 163
 - 4-substituted Glu analogs 163–168
 - binding affinities of 4-alkylGlu analogs at native iGluRs and 165–167
 - DPAG, selective inhibitor of the EAAT2 subtype 168
 - substituted benzyl esters 38
 - sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) 370
 - synthesized peptides, sequences and structures 509
 - synthetic glycopeptides 324
 - synthetic peptides 2
- t**
- tachykinin NK1 receptor antagonists 185
 - target protein 247
 - L-tartaric acid 204
 - Taxus baccata* 228
 - T cells 383
 - temporary α acarboxy protection 39, 41
 - tetrahydrofuran (THF) 104, 343
 - tetra-*n*-butylammonium fluoride (TBAF) 333
 - tetrathiomolybdate salt 32
 - tetravalent RAFT glycoclusters 366
 - thermal Huisgen cycloaddition 102
 - thioether group of Met, protection 53
 - through oxidation 53
 - N*-thioformyl glycosides 363
 - thioibotenic acid (TIBO)
 - chemical structures of 161
 - design and synthesis 161, 162
 - β -thiol protections of Cys 52
 - threonine 359
 - mutant dendrimer 505
 - tilidine synthesis 184
 - tissue-type plasminogen activator 465
 - transesterification 200
 - triazoles 101
 - ^1H -triazole-CH NMR resonances 121
 - linked AFGP analogs 376
 - modified peptidomimetics synthesis, building blocks for 106–109
 - as peptide bond isosteres 102
 - peptidomimetic, synthesis 117
 - 1,4-triazoles
 - β -turn-induced 115
 - use of 111
 - trimer, solution-phase synthesis 116
 - uses of 116
 - triethylamine (TEA) 9, 191, 421
 - trifluoroacetic acid (TFA) 5, 157, 215, 326, 419, 493
 - trifluoroacetic anhydride (TFAA) 5, 7, 59
 - tris-[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl] amine (TBTA) 104
 - tris(2-carboxyethyl)phosphine (TCEP) 344, 345, 350, 378
 - trypsin variants 465
 - tumor-targeting agents 258
 - tumor-targeting drugs 268
 - tyrosine 331, 336, 359, 421
- u**
- ubenimex 205, 209
 - ubiquitin 484
 - unprotected amino acids 1
 - urea-linked glycosides 363
 - urethanes
 - bond formation 15–17
 - cleavage 17–19
 - by β -elimination 19
 - derived from primary alcohols 15
 - allyloxycarbonyl (Alloc) group 25
 - benzyloxycarbonyl (Cbz or Z) group 15–19
 - cleaved by β -elimination 19–24
 - cleaved via Michael-type addition 24
 - derived from, secondary alcohols 25

- derived from, tertiary alcohols 25
- Boc analogs 28, 29
- *tert*-butoxycarbonyl (Boc) group 25, 26
- deprotection 27
- lewis acids 28
- organosilanes 28
- oxidizing agent 28
- preparation 26, 27
- protic acids 27
- removal of Boc groups 28
- modes of fission 15
- protected NCAs 31
- protectors
- formation of dipeptide impurities during 29, 30
- nitrogen of α -amino acid *N*-carboxy anhydrides (NCAs), protection of 31
- urethanes via transprotection, introduction of 30, 31
- structure 15
- US Food and Drug Administration (FDA) 253, 256, 260, 264, 266

v

- vapreotide 261
- vascular endothelial growth factor receptor 1 (VEGFR1) 110
- potential VEGFR1 antagonists, synthesis of 111
- vasopressin 250
- Veber–Hirschmann cyclic hexapeptide cyclo (-PFwKTF-) 283

w

- Wang resin 329
- Weinreb amide derivatives 108
- (*S*)-willardiine (WILLA) 160
- Willebrand factor 251

x

- X-ray crystallography 177, 461
- X-ray crystal structure analysis 101
- of peptidomimetics 115

z

- zwitterionic intermediate 295

